Earnings History Data for Ocuphire Pharma (OCUP) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Ocuphire Pharma
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13-08-2024 | PM | OCUP | Ocuphire Pharma | 43.00 | -0.30 | -0.29 | 0.00 | Ocuphire Pharma GAAP EPS of -$0.30, revenue of $1.11M [8/13/2024 8:48 AM] |
1.31 | -0.34 (-20.54%) |
1.60 | -0.05 (-3.32%) |
1.27 - 4.50 | 709,272 | 120,000 | 2,550 | ||
| 10-05-2024 | PM | OCUP | Ocuphire Pharma | 47.00 | -0.29 | -0.18 | 0.00 | Ocuphire Pharma GAAP EPS of -$0.29 misses by $0.20, revenue of $1.71M misses by $2.96M [5/10/2024 8:05 AM] |
1.70 | -0.26 (-13.14%) |
0.0 | 0.0 (0.00%) |
1.50 - 6.60 | 451,530 | 200,000 | 0 | ||
| 08-03-2024 | PM | OCUP | Ocuphire Pharma | 55.00 | -0.21 | -0.07 | 0.00 | Ocuphire Pharma GAAP EPS of -$0.21 misses by $0.21, revenue of $1.69M misses by $4.27M [3/8/2024 8:25 AM] |
2.01 | -0.37 (-15.55%) |
2.32 | -0.06 (-2.52%) |
1.93 - 6.60 | 773,163 | 150,000 | 11,322 | ||
| 04-11-2022 | AH | OCUP | Ocuphire Pharma | 45.00 | -0.22 | -0.30 | 0.00 | Ocuphire Pharma GAAP EPS of -$0.22 beats by $0.08 [11/4/2022 4:40 PM] |
2.09 | -0.10 (-4.61%) |
2.20 | 0.01 (0.46%) |
1.78 - 5.50 | 45,228 | 50,000 | 494 | ||
| 12-08-2022 | PM | 8:00 AM ET (Aug 12) |
OCUP | Ocuphire Pharma, Inc. | 37.57 | -0.25 | -0.37 | -0.52 | Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08 [8/12/2022 7:53 AM] |
2.54 | -0.25 (-8.96%) |
2.57 | -0.22 (-7.89%) |
1.78 - 5.50 | 159,333 | 190,000 | 1,293 | |
| 24-03-2022 | PM | 7:00 AM ET (Mar 24) |
OCUP | Ocuphire Pharma, Inc. | 71.99 | -0.35 | -0.29 | 0.00 | Ocuphire Pharma GAAP EPS of -$0.35 misses by $0.09 [3/24/2022 9:02 AM] |
4.20 | 0.25 (6.33%) |
3.90 | -0.05 (-1.27%) |
2.59 - 7.28 | 305,714 | 181,749 | 6,343 | |
| 12-11-2021 | PM | OCUP | Ocuphire Pharma, Inc. | 70.46 | -0.25 | 0.00 | 0.00 | Ocuphire Pharma EPS beats by $0.09 [11/12/2021 7:39 AM] |
4.00 | 0.04 (1.01%) |
4.15 | 0.11 (2.72%) |
3.82 - 13.81 | 160,468 | 100,000 | 404 | ||
| 12-08-2021 | PM | 8:00 AM ET (Aug 12) |
OCUP | Ocuphire Pharma, Inc. | 53.88 | -0.52 | 0.00 | -2.48 | Ocuphire Pharma EPS misses by $0.08 [8/12/2021 7:45 AM] |
4.55 | -0.20 (-4.21%) |
4.69 | -0.06 (-1.26%) |
3.68 - 13.81 | 228,202 | 770,000 | 3,153 | |
| 07-05-2021 | PM | OCUP | Ocuphire Pharma, Inc. | 52.69 | -0.47 | -0.37 | -0.60 | Ocuphire Pharma EPS beats by $0.36 [5/7/2021 8:49 AM] |
4.41 | -0.20 (-4.34%) |
4.55 | -0.06 (-1.30%) |
3.68 - 14.80 | 169,062 | 290,000 | 600 | ||